This company is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
InDex Pharmaceuticals Holding Résultats passés
Passé contrôle des critères 0/6
InDex Pharmaceuticals Holding has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 89.5% per year.
Informations clés
2.7%
Taux de croissance des bénéfices
53.7%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 30.5% |
| Taux de croissance des recettes | 89.5% |
| Rendement des fonds propres | -23.9% |
| Marge nette | -52.1% |
| Prochaine mise à jour des résultats | 20 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost
Jun 13
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21Ventilation des recettes et des dépenses
Comment InDex Pharmaceuticals Holding gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 108 | -56 | 171 | 0 |
| 31 Dec 23 | 98 | -95 | 188 | 0 |
| 30 Sep 23 | 98 | -46 | 143 | 0 |
| 30 Jun 23 | 98 | -12 | 134 | 0 |
| 31 Mar 23 | 1 | -123 | 156 | 0 |
| 31 Dec 22 | 1 | -100 | 140 | 0 |
| 30 Sep 22 | -2 | -67 | 123 | 0 |
| 30 Jun 22 | -2 | -92 | 127 | 0 |
| 31 Mar 22 | 0 | -113 | 117 | 0 |
| 31 Dec 21 | 0 | -103 | 100 | 0 |
| 30 Sep 21 | 3 | -90 | 86 | 0 |
| 30 Jun 21 | 3 | -70 | 59 | 0 |
| 31 Mar 21 | 0 | -43 | 35 | 0 |
| 31 Dec 20 | 0 | -57 | 41 | 0 |
| 30 Sep 20 | 0 | -73 | 53 | 0 |
| 30 Jun 20 | 0 | -92 | 73 | 0 |
| 31 Mar 20 | 0 | -95 | 80 | 0 |
| 31 Dec 19 | 0 | -88 | 83 | 0 |
| 30 Sep 19 | 0 | -84 | 83 | 0 |
| 30 Jun 19 | 0 | -72 | 71 | 0 |
| 31 Mar 19 | 0 | -81 | 80 | 0 |
| 31 Dec 18 | 1 | -82 | 81 | 0 |
| 30 Sep 18 | 0 | -82 | 82 | 0 |
| 30 Jun 18 | 0 | -80 | 80 | 0 |
| 31 Mar 18 | 0 | -69 | 69 | 0 |
| 31 Dec 17 | 0 | -73 | 63 | 0 |
| 30 Sep 17 | 0 | -67 | 54 | 0 |
| 30 Jun 17 | 0 | -61 | 48 | 0 |
| 31 Mar 17 | 0 | -56 | 41 | 0 |
| 31 Dec 16 | 0 | -41 | 34 | 0 |
| 30 Sep 16 | 0 | -31 | 28 | 0 |
| 30 Jun 16 | 0 | -31 | 29 | 0 |
| 31 Mar 16 | 0 | -29 | 28 | 0 |
| 31 Dec 15 | 0 | -30 | 28 | 0 |
| 30 Sep 15 | 0 | -33 | 30 | 0 |
| 30 Jun 15 | 0 | -36 | 32 | 0 |
| 31 Mar 15 | 23 | -25 | 42 | 0 |
| 31 Dec 14 | 45 | -15 | 52 | 0 |
| 31 Dec 13 | 1 | -68 | 62 | 0 |
Des revenus de qualité: INDEX is currently unprofitable.
Augmentation de la marge bénéficiaire: INDEX is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: INDEX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.
Accélération de la croissance: Unable to compare INDEX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: INDEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.1%).
Rendement des fonds propres
ROE élevé: INDEX has a negative Return on Equity (-23.93%), as it is currently unprofitable.